Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Tesamorelin Study Comparison — VAT Reduction Mechanisms and Outcomes

Tesamorelin 2mg daily GHRH analog → pulsatile GH secretion → HSL activation in visceral adipocytes 15.2% (−20.2 cm² absolute) Minimal. No significant SAT change Neutral. No impairment in glucose tolerance or HbA1c Moderate. 40% VAT regain within 26 weeks off-t

This comparison does not assign a generated winner or score.

  • Tesamorelin 2mg daily
  • GHRH analog → pulsatile GH secretion → HSL activation in visceral adipocytes
  • 15.2% (−20.2 cm² absolute)
  • Minimal. No significant SAT change
  • Neutral. No impairment in glucose tolerance or HbA1c
  • Moderate. 40% VAT regain within 26 weeks off-treatment
  • Semaglutide 2.4mg weekly
  • GLP-1 receptor agonist → appetite suppression + delayed gastric emptying → caloric deficit
  • 8–12% VAT (as part of 15% total body weight loss)
  • Proportional. Whole-body fat reduction including SAT
  • Improved. Enhanced insulin secretion and peripheral sensitivity
  • High. 60–70% total weight regain within 12 months off-treatment
  • Caloric restriction (500 kcal/day deficit)
  • Energy deficit → whole-body lipolysis mediated by catecholamines
  • 5–8% VAT (highly variable by adherence)
  • Proportional. SAT and VAT lost equally
  • Variable. Improves acutely but metabolic adaptation limits long-term benefit
  • Very high. 80–95% weight regain within 5 years
  • Professional Assessment
  • Tesamorelin is the only intervention with documented VAT-specific reduction without proportional subcutaneous loss, making it uniquely suited for visceral adiposity and metabolic risk management rather than cosmetic weight loss. The pulsatile GH mechanism avoids insulin resistance while maintaining lipolytic efficacy. Discontinuation rebound is moderate. Better than lifestyle alone, worse than maintained GLP-1 therapy.